CHU de Clermont-Ferrand
Clermont-Ferrand, France, 63000
Location contact
Magali VIDAL
CONTACT
Magali VIDAL
PRINCIPAL_INVESTIGATOR
CONTACT
NCT Number: NCT07313865
Enterococci are pathobionts of the human intestinal microbiota: they colonize the gastrointestinal tract as well as the skin, urine, wounds, bile, the oral cavity and endodontic canal, and medical devices (urinary catheters, venous catheters, etc.). They are responsible for urinary, dental, bloodstream, endocardial, biliary, and gastrointestinal infections.
Enterococcus faecalis is the enterococcus most frequently isolated from clinical specimens. It is the third leading cause of infective endocarditis (infection of the cardiac valves) and the leading cause of endocarditis following TAVI (transcatheter aortic valve implantation via the femoral route). E. faecalis infective endocarditis (EFIE) is severe and difficult to treat, with a particularly high relapse rate despite appropriate antibiotic therapy.
Cardiac valve contamination is always secondary to E. faecalis bacteremia, particularly in cases of isolated E. faecalis bacteremia (EFIB), defined by the absence of an identifiable portal of entry. Once in the bloodstream, the bacterium adheres to the valvular endothelium (healthy or damaged) through specific virulence factors, including endocarditis- and biofilm-associated pili (ebp), the collagen adhesin Ace, and aggregation substance (Agg).
The classical portals of entry for EFIE are infections of the urinary tract and the gastrointestinal tract. However, despite extensive investigations, the source of infection remains unidentified in more than 50% of cases. An imbalance of the intestinal microbiota, leading to overgrowth and subsequent translocation of E. faecalis from the digestive tract into the bloodstream, could explain the absence of an identifiable portal of entry during routine clinical and paraclinical evaluations. This plausible hypothesis remains largely unexplored to date. A better understanding of the underlying pathophysiology-particularly gut dysbiosis and the pathogen's capacity for intestinal translocation-could improve the prevention of EFIE occurrence and relapse.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Clermont-Ferrand, France, 63000
Magali VIDAL
CONTACT
Magali VIDAL
PRINCIPAL_INVESTIGATOR
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants in the case group will undergo microbiological sampling consisting of four swabs: two rectal swabs, one oral swab, and one skin swab from the inguinal fold.
Participants in the control group will undergo a single rectal swab. The samples will be collected for microbiological analysis.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Contact information is provided by the study sponsor or research team.
University Hospital, Clermont-Ferrand
Other
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditisléter
Acronym: BAC-ENDO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07282002
Cardiovascular Diseases, Endocarditis
View Trial DetailsNCT07523646
Anemia, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT07511673
Cardiovascular Diseases, Endocarditis
Gothenburg, Sweden
View Trial DetailsNCT07529730
Cardiovascular Diseases, Endocarditis
Alessandria, AL, Italy
View Trial Details